---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049866"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:35:27.240261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Esperion Q3 total revenue up 69% to $87.3M; net loss $0.16/share

## Summary
- U.S. net product revenue $40.7M (+31% YoY); total collaboration revenue $46.7M (+128% YoY).
- Net loss $31.3M ($0.16 diluted EPS) vs $29.5M loss ($0.15) in Q3 2024.
- Settled with Dr. Reddy's and three other ANDA filers; generic entry blocked until April 2040.
- Partner Otsuka received Japan approval and preliminary pricing for NEXLETOL, triggering milestone payments.
- Company reiterates 2025 opex guidance of $215-235M; expects sustainable profitability from Q1 2026.

## SEC filing metadata
- accession: 0001628280-25-049866
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025049866/0001628280-25-049866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025049866/espr-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049866
- JSON: https://secwatch.observer/filing/0001628280-25-049866.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.